SAS Output

21-OCT-2018 6:10

LUNG ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1400-SCCA,Adv, Biomarker Master 1 Y 1 Specimen Submission   1811 413 205 89 25 7 07/08/2014 436 204
            1811 413 205 89 25 7      
 
    2 Y 17 S1400G   62 31 8 0 0 0      
        2 S1400A   160 0 0 0 0 0 07/08/2014    
        21 S1400F   106 103 59 35 18 1      
        25 S1400K   52 52 32 12 3 1      
        3 S1400B   53 0 0 0 0 0      
        4 S1400C   88 0 0 0 0 0      
        5 S1400D   92 0 0 0 0 0      
        6 S1400E   16 0 0 0 0 0      
        7 S1400I   700 67 1 0 0 0      
            1329 253 100 47 21 2      
 
    3 P 10 S1400I   13 5 0 0 0 0      
        18 S1400G   10 2 0 0 0 0      
        22 S1400F   24 24 12 5 0 0      
        8 S1400B   1 0 0 0 0 0 07/08/2014    
            48 31 12 5 0 0      
 
    4 P 23 S1400F   3 3 1 0 0 0 07/08/2014    
            3 3 1 0 0 0      
 
  S1400A-Non-Match: MEDI4736 1 N 1 MEDI4736 140 78 0 0 0 0 0 07/31/2014    
        2 Docetaxel   38 0 0 0 0 0      
            116 0 0 0 0 0      
 
    2 Y 3 MEDI4736 140 4 0 0 0 0 0 07/31/2014    
            4 0 0 0 0 0      
 
  S1400F-Non-Match: MEDI4736 + Tremelimumab 1 Y 1 MEDI4736 + Tremelimumab 132 39 39 24 16 6 2 11/30/2017 446 210
            39 39 24 16 6 2      
 
  S1400K-c-Met: ABBV-399 (Process II) 1 T 1 ABBV-399 (Process II) 44 28 28 22 7 1 1 03/16/2018 462 221
            28 28 22 7 1 1      
 
  S1619-Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC 1 Y 1 Chemotherapy + Atezolizumab 28 5 5 5 4 1 1 07/16/2018 76 26
            5 5 5 4 1 1      
 
  8811-NSCLC, Stage III,ChemoRT+ABT-888 1 N 5 RT+Pac+Carbo+blinded drug 132 18 0 0 0 0 0 01/24/2013    
        6 RT+Pac+Carbo+blinded drug   14 0 0 0 0 0      
            32 0 0 0 0 0      
 
    2 N 8 Pac + Carbo + blinded drug 132 23 4 0 0 0 0 01/24/2013    
            23 4 0 0 0 0      
 
Yes A081105-ALCHEMIST1, EGFR mut, Erlotinib 1 E Total Registrations   42 14 4 2 1 0 04/01/2015 483 248
            42 14 4 2 1 0      
 
  A151216-ALCHEMIST0 - screening 1 E Total Registrations   607 223 117 59 8 0 12/16/2014 478 249
            607 223 117 59 8 0      
 
  C30610-SCLC, Thoracic RT 1 E Total Registrations   56 4 1 0 0 0 05/14/2008 212 116
            56 4 1 0 0 0      
 
  E4512-ALCHEMIST2, ALK mut, Crizotinib 1 E Total Registrations   9 3 2 1 0 0 02/29/2016 470 248
            9 3 2 1 0 0      
 
  NRGCC003-SCLC, PCI or HA-PCI 1 E Total Registrations   4 0 0 0 0 0 10/20/2016 328 150
            4 0 0 0 0 0      
 
    2 E Total Registrations   4 0 0 0 0 0 10/20/2016    
            4 0 0 0 0 0      
 
No A151216-ALCHEMIST0 - screening 0 E Total Registrations   618 227 122 63 11 3 12/16/2014 478 249
            618 227 122 63 11 3      
 
  EA5142-ALCHEMIST3, Non-match, Nivolumab 1 E Total Registrations   74 50 31 15 5 2 08/03/2016 449 242
            74 50 31 15 5 2      
 
  EA5161-Lung, ED-SCLC, Cis/Carbo and Eto +/- Nivo 1 E Total Registrations   11 11 11 9 5 1 06/26/2018 238 114
            11 11 11 9 5 1      
 

21-OCT-2018 6:10

LUNG Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date
S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC 2 Surgery 03-Nov-17
  3 Maintenance 03-Nov-17
S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac 1 Randomization 09-Aug-18

21-OCT-2018 6:10

LUNG Recently Closed Studies Accrual Report

The REPORT Procedure

Detailed and/or summarized report

Table 1

OPEN Study Date
Closed
Reg. Arm Total
Regs
Regs
Last
30 Days
Regs
Last
7 Days
N 8811-NSCLC, Stage III,ChemoRT+ABT-888 17-Oct-18 2 7 Pac + Carbo + ABT-888 80mg 14 0 0
        8 Pac + Carbo + blinded drug 23 0 0
T S1400K-c-Met: ABBV-399 (Process II) 18-Oct-18 1 1 ABBV-399 (Process II) 28 1 1